Fezolinetant Tied to Fewer Hot Flashes, Less Depression, and Anxiety in Real-World Study

The nonhormonal drug fezolinetant was associated with significant improvements in bothersome vasomotor symptoms (VMS) and in depression and anxiety scores as early as 4 weeks after treatment initiation, according to a real-world study presented at The Menopause Society 2026 Annual Meeting in San Diego.